Login to Your Account



Other News To Note


Wednesday, June 13, 2012
• Affiris AG, of Vienna, Austria, initiated a global Phase I trial of its Parkinson's vaccine candidate, PD01A. The vaccine is directed against alpha-synuclein, a protein thought to cause the onset and progression of the disease, and it aims to educate the immune system to generate antibodies directed against the protein. The trial, being conducted in Vienna, involves up to 32 patients, with primary endpoints of safety and tolerability.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription